



INTERNATIONAL CONSORTIUM *for*
INNOVATION & QUALITY
in PHARMACEUTICAL DEVELOPMENT



ACS Green Chemistry Institute
Pharmaceutical Roundtable

Useful Green Chemistry Metrics

- *Scientific Update webinar*
- *September 4th, 2019*
- *Speakers: Stefan G. Koenig, Ph.D.
Erin M. O'Brien, Ph.D.*

Outline



Intro to Green Chemistry



Discussion of current metrics: PMI, cEF



How Green is your process? *Check iGAL!*



Conclusions

Why should we care about Green Chemistry?

*The global emphasis on sustainability is expected to continue to intensify and the pharmaceutical industry should find ways to meet patient needs via sustainable manufacturing technology to **minimize its environmental footprint***



Why Apply Green Chemistry?

In terms of waste.....



PHARMACEUTICAL &
GENERIC INDUSTRIES MAY
PRODUCE ≥ 100 MILLION KG
APIS PER YEAR *1



EF ≥ 150 KG WASTE PER KG
API ($> 99.3\%$) \rightarrow
 ≥ 15 BILLION KG OF CO-
PRODUCED WASTE



ANNUAL WASTE DISPOSAL
COST OF \sim **\$30 BILLION**



**OPPORTUNITY FOR
INDUSTRY TO UTILIZE
GREEN CHEMISTRY TO TRIM
BOTH PROCESS INPUTS AND
WASTE, AND CREATE \$
BILLIONS IN ECONOMIC,
ENVIRONMENTAL, AND
SOCIAL VALUE**

*1 B. W. Cue, (2012) Green Chemistry Strategies for Medicinal Chemists, in Green Techniques for Organic Synthesis and Medicinal Chemistry (eds. Zhang, W., and Cue, B. W.). John Wiley & Sons, Chichester, UK.

What is Green Chemistry?

Noyori - "...green chemistry is not just a catchphrase. It is an indispensable principle of chemical research that will sustain our civilized society in the twenty-first century and further into the future."

R. Noyori, Synthesizing our future, *Nature Chemistry*, 2009, 1, 5-6.



Innovation aimed at design, development, and implementation of ...



chemical products, reactions, and processes that ...



minimize hazardous substances and are inherently safe ...




reduce waste and environmental footprint, while ...



improving efficiency and economics




Green Chemistry = Efficient Process



- innovative chemical methodologies and new manufacturing platforms;
- consolidation of high-yielding reactions into a minimal number of unit operations with common solvents and limited intermediate isolations;
- vertical integration of advanced starting materials prepared from commodity chemicals (use of feedstock chemicals).

Evolution of Green Chemistry



*1 R. B. Woodward, *Perspectives in Organic Chemistry*, Interscience, 1956, pp. 155–184.

*2 R. A. Sheldon, Organic synthesis; past, present and future. *Chem. Ind. (London)*, 1992, 903-906.


*3 P. T. Anastas & J. C. Warner, *Green Chemistry: Theory and Practice*, Oxford University Press, 1998.

*4 F. Roschangar et al. *Green Chemistry*, 2017, **19**, 281.

Selection Guides

- Multiple selection guides available
 - Solvent selection guides
 - ACS GCI Pharmaceutical Roundtable (free of charge)
 - Safety, health and environmental impact of solvents
 - Other solvents guides from major pharmaceutical companies are also available online
 - Reagents guide
 - Green conditions for common transformations (e.g. amide formation, oxidation, etc.)
 - GSK (*Green Chem.* **2013**, *15*, 1542-1549)
 - ACS GCI Pharmaceutical Roundtable (free of charge)
- www.acs.org/gcipharmaroundtable

Reagents + raw materials +
process aides



Solvents + Water

Green Chem. **2017**, *19*, 281–285

Table 1: CHEM21 solvent guide: ethers, hydrocarbons, halogenated


Family	Solvent	CAS	BP (°C)	FP (°C)	Worst H3xx*	H4xx	Safety score	Health score	Env. score	Ranking by default	Ranking after discussion #
Ethers	Diethyl ether	60-29-7	34	-45	H302	none	10	3	7	Hazardous	Highly hazardous
	Diisopropyl ether	108-20-3	69	-28	H336	none	9	3	5	Hazardous	Hazardous
	MTBE	1634-04-4	55	-28	H315	none	8	3	5	Hazardous	Hazardous
	ETBE	637-92-3	72	-19	H336	none	7	3	3	Problematic	Problematic
	TAME	994-05-8	86	-7	H302	none	6	2	3	Recommended	Recommended
	CPME	5614-37-9	106	-1	H302	H412	7	2	5	Problematic	Problematic
	THF	109-99-9	66	-14	H351	none	6	7	5	Problematic	Problematic
	Me-THF	96-47-9	80	-11	H318	none	6	5	3	Problematic	Problematic
	1,4-Dioxane	123-91-1	101	12	H351	none	7	6	3	Problematic	Hazardous
	Anisole	100-66-3	154	52	none	none	4	1	5	Problematic	Recommended
DME	110-71-4	85	-6	H360	none	7	9	3	Hazardous	Hazardous	
Hydrocarbons	Pentane	109-66-0	36	-40	H304	H411	8	3	7	Hazardous	Hazardous
	Hexane	110-54-3	69	-22	H361	H411	8	7	7	Hazardous	Hazardous
	Heptane	142-82-5	98	-4	H304	H410	6	2	7	Problematic	Problematic
	Cyclohexane	110-82-7	81	-17	H304	H410	6	3	7	Problematic	Problematic
	Me-Cyclohexane	108-87-2	101	-4	H304	H411	6	2	7	Problematic	Problematic

Solvent Guides


- Solvent & water contribute >85% to the process mass intensity PMI
- Great need to reduce use and hazard of solvents

Solvent Selection Tool

- acsgcipr.org/tools-for-innovation-in-chemistry
- Select solvents based on molecular and physical properties, EH&S characteristics, ICH guidelines and more.
- 272 Solvents in data set
- Interactive visualizations




Reagent Guides



Bromination
Fluorination
Chlorination
Iodination
Metals Removal
Chiral Hydrogenation
Oxidation to Acids
Suzuki Rxn
Buchwald-Hartwig Rxn

Venn Diagram




Reagent
Guides

Manufacturing Components


Life Cycle Assessment ^{*1}

- Solvent selection
- Reagent selection
- Sustainable metals
- Carbon footprint
- Waste treatment



^{*1} C. Jiménez-González and M. R. Overcash, The Evolution of Life Cycle Assessment in Pharmaceutical and Chemical Applications – a Perspective, *Green Chem.*, 2014, **16**, 3392–3400.

Metrics: You can't improve what you don't measure!



Green Metrics

Metric	Abbreviation	Formula	Optimum Value
Resource Efficiency			
Chemical Yield	CY	$\frac{m(\text{Product}) \times MW(\text{Raw Material}) \times 100}{m(\text{Raw Material}) \times MW(\text{Product})}$	100%
Atom Economy	AE	$\frac{MW(\text{Product}) \times 100}{\sum MW(\text{Raw Materials}) + \sum MW(\text{Reagents})}$	100%
Environmental Impact Factor	E factor	$\frac{\sum m(\text{Input Materials excl. Water}) - m(\text{Product})}{m(\text{Product})}$	0 $\frac{kg}{kg}$
Effective Mass Yield	EMY	$\frac{m(\text{Product}) \times 100}{\sum m(\text{Raw Materials}) + \sum m(\text{Reagents})}$	100%
Mass Intensity	MI	$\frac{\sum m(\text{Input Materials excl. Water})}{m(\text{Product})}$	1 $\frac{kg}{kg}$
Reaction Mass Efficiency	RME	$\frac{m(\text{Product}) \times 100}{\sum m(\text{Raw Materials})}$	100%
Carbon Efficiency	CE	$\frac{m(\text{Carbon in Product}) \times 100}{\sum m(\text{Carbon in Raw Materials})}$	100%
Mass Productivity	MP	$\frac{m(\text{Product}) \times 100}{\sum m(\text{Input Materials excl. Water})} = \frac{100}{MI}$	100%
Process Mass Efficiency	PME	$\frac{m(\text{Product}) \times 100}{\sum m(\text{Input Materials incl. Water})} = \frac{100}{PMI}$	100%
Process Mass Intensity	PMI	$\frac{\sum m(\text{Input Materials incl. Water})}{m(\text{Product})}$	1 $\frac{kg}{kg}$
Reaction Mass Intensity	RMI	$\frac{\sum m(\text{Raw Materials}) + \sum m(\text{Reagents})}{m(\text{Product})} = \frac{1}{EMY}$	1 $\frac{kg}{kg}$
Optimum Efficiency	OE	$\frac{RME \times 100}{AE}$	100%
simple E factor	<u>sEF</u>	$\frac{\sum m(\text{Raw Materials}) + \sum m(\text{Reagents}) - m(\text{Product})}{m(\text{Product})} = RMI - 1$	0 $\frac{kg}{kg}$
complete E factor	<u>cEF</u>	$\frac{\sum m(\text{Input Materials incl. Water}) - m(\text{Product})}{m(\text{Product})} = PMI - 1$	0 $\frac{kg}{kg}$




FREE PMI CALCULATOR *1

Process Mass Intensity

Considers all process materials including water and workup chemicals

$$PMI = \frac{\sum m(\text{Input Materials incl. Water})}{m(\text{Product})}$$

*1 Available from: <https://www.acs.org/content/acs/en/greenchemistry/research-innovation/tools-for-green-chemistry.html>.



Example of route change between Phase 1 and Phase 2



Reduce steps, reduce solvent, reduce # of isolations



= Cost of molecule drops by 80%

PMI Prediction Tool

- [acscipr.org/tools-for-innovation-in-chemistry](https://www.acscipr.org/tools-for-innovation-in-chemistry)
- Predicts a range of probable process efficiencies of proposed synthetic routes
- Uses historical PMI data from pharma companies and predictive analytics (Monte Carlo simulations) to estimate the probable PMI ranges
- Assess and compare potential route changes


Overall PMI

Step Metrics

Step Yield vs Step PMI

The plots below show the distribution of the intermediate compounds needed to produce one unit mass of final product. The panel labeled waste is the sum of all processing masses that are not chemical intermediates

You have selected intermediates: A, B, C, D product: D



*1 Available from: <https://www.acs.org/content/acs/en/greenchemistry/research-innovation/tools-for-green-chemistry.html>.

cE factor


$$cEF = \frac{\sum m(\text{Input Materials incl. Water}) - m(\text{Product})}{m(\text{Product})}$$

Environmental Impact factor (EF)
measures total waste relative to product

- High E factor indicates more waste generation and negative environmental impact
- Ideal E factor is 0

Complete E factor or cEF analyzes total waste stream and accommodates current trend in pharmaceutical industry to *include water*

cE factor



Financial Value of Green Chemistry

51% E-Factor Reduction

>65% Overall Cost Reduction

Process 1

Step	Yield	E-Factor
1	73%	93
2	81%	66
3	92%	11
4	82%	61
Total	45%	231

Process 2


Step	Yield	E-Factor
1	68%	30
2	92%	22
3	86%	23
4	87%	33
5	96%	24
Total	45%	132

Process 3

Step	Yield	E-Factor
1	98%	17
2	89%	21
3	86%	23
4	87%	30
5	95%	23
Total	62%	114

E-Factor represents kg waste produced during manufacture of 1 kg of drug substance


Cost and Metrics



Late stage development compounds and marketed products


innovation Green Aspiration Level (iGAL)






Tecfidera


≠



Viagra



How can you determine if your process is green when not every target molecule is the same?



How can you determine
if your process is green
when not every target
molecule is the same?

Hole	1	2	3	4	5	6	7
Par	4	3	5	3	4	4	5

How can you determine
if your process is green
when not every target
molecule is the same?

innovation Green Aspiration Level (iGAL)




Green Chemistry


Volume 20 | Number 10 | 21 May 2018 | Pages 2161–2400

Cutting-edge research for a greener sustainable future
rsc.li/greenchem

Created by 12
Pharmaceutical Companies
and Two Academic
Institutions



Dabigatran



iGAL

CAPTURING THE VALUE
OF GREEN CHEMISTRY
INNOVATION

- Fair RPG-based Rating Method
- Simple
- Consistent
- Complexity-Adjusted
- Standardized
- Quantitative

ISSN 1463-9262



COMMUNICATION
Frank Roschangar et al.
Inspiring process innovation via an improved green manufacturing
metric: iGAL

iGAL is a unifying green chemistry metric that takes into account molecular complexity with a fixed goal to target the most innovative, mass-efficient process.

iGAL is based on (salt-)Free Molecular Weight (FMW) and rewards process complexity reduction as measured in Relative Process Greenness (RPG).


$$iGAL = 0.344 \times FMW \left[\frac{kg \text{ waste}}{kg \text{ API}} \right]$$

$$RPG = \frac{iGAL}{cEF} \times 100\% \text{ with } cEF = PMI - 1$$

innovation Green Aspiration Level (iGAL)

- **Process Complexity** = sum of process **construction steps**,^{*1} (stereoselective) skeletal API C–C, C–X, C–H, and X–H bond forming steps:
- functional group interconversions
- reductions / oxidations directly establishing correct functionality, stereochemistry, and oxidation state in final product
- chiral chromatography or chemical resolution steps

$$\text{Complexity} = \sum \text{Construction Steps}$$



*1 Similar to definition used by T. Gaich, and P. S. Baran, Aiming for the Ideal Synthesis, *J. Org. Chem.*, 2010, **75**, 4657–4673.

innovation Green Aspiration Level (iGAL)

$$\text{Complexity} = \sum \text{Construction Steps}$$

- **Concession steps** = “non-constructive” reactions forming skeletal but racemic API bonds or non-skeletal API bonds:
- protecting group manipulations
- functional group interconversions not leading to final API functionality
- racemic reductions and oxidations where chirality is needed
- recrystallization steps




innovation Green Aspiration Level (iGAL)

$$\text{Complexity} = \sum \text{Construction Steps}$$

- Only the sum of construction steps are included in complexity

One significant rule for calculation: track back to non-custom materials with \leq \$100 per mole from chemical vendor catalog


Greenness via an innovation Green Aspiration Level (iGAL)



- **FMW** (“salt-free” MW of API) is
 - an improved proxy for molecular complexity *
 - a **fixed** measure of complexity
- FMW enables us to derive **iGAL** as a **commercial goal** for co-produced waste:

* statistical analysis of best fit of selected complexity parameters (no. of chiral centers, fluorine functional groups, and rings)

Greenness via an innovation Green Aspiration Level (iGAL)




- **FMW** (“salt-free” MW of API) is
 - an improved proxy for molecular complexity *
 - a **fixed** measure of complexity
- FMW enables us to derive **iGAL** as a **commercial goal** for co-produced waste:
- Statistical analysis of 64 drug manufacturing processes encompassing 703 steps across 12 companies

$$iGAL = 0.344 \times FMW \left[\frac{kg \text{ waste}}{kg \text{ API}} \right]$$

- 0.344 = data-derived average waste complete E-Factor (cEF) per unit of average commercial drug FMW

* statistical analysis of best fit of selected complexity parameters (no. of chiral centers, fluorine functional groups, and rings)

Greenness via an innovation Green Aspiration Level (iGAL)




$$RPG = \frac{iGAL}{cEF} \times 100\%$$

- FMW (“salt-free” MW of API) is
 - an improved proxy for molecular complexity *
 - a **fixed** measure of complexity
 - FMW enables us to derive **iGAL** as a **commercial goal** for co-produced waste:
 - Statistical analysis of 64 drug manufacturing processes encompassing 703 steps across 12 companies
- $$iGAL = 0.344 \times FMW \left[\frac{kg \text{ waste}}{kg \text{ API}} \right]$$
- 0.344 = data-derived average waste complete E-Factor (cEF) per unit of average commercial drug FMW

iGAL defines greenness of a process relative to industry averages across phases via **Relative Process Greenness (RPG)**


* statistical analysis of best fit of selected complexity parameters (no. of chiral centers, fluorine functional groups, and rings)

Case Study: Dabigatran process evolution



- First generation synthesis: Few desirable reagents and conditions, many rework steps
- Second generation route: Streamlining, including considerations to waste co-production

Case Study: Dabigatran process evolution



- First generation synthesis: Few desirable reagents and conditions, many rework steps
- Second generation route: Streamlining, including considerations to waste co-production
- Final (third) generation process: Omission of protecting groups, inclusion of catalytic reagents and improved volumes, selectivities, and yields

How to inspire green process innovation via iGAL?



Use **iGAL** to capture value and innovation impact



Communicate value



Motivate innovation via a new **Green Chemistry Innovation Scorecard**

RPG rating matrix for process evaluation:

based on average commercial waste

Percentile (PCTL)	Code	Rating	Minimum RPG for		
			Early dev.	Late dev.	Commercial
90%		Excellent	66%	146%	222%
70%		Good	48%	103%	168%
40%		Average	29%	59%	113%
		Below average			

Green chemistry innovation scorecard


Dabigatran (FMW = 628 g / mol)

Phase of drug mfg	cEF [kg/kg]	Steps	Complexity	RPG	Scorecard rating	Innovation Impact = % RPG upgrade
Early dev (1 st gen)	252	16	11	86%	---	---
Late dev (2 nd gen)	167	13	11	129%	Good	44%
Commercial (3rd gen)	89	13	10	243%	Excellent	157%


- **process improvement/innovation** is quantified via RPG upgrade & correlates to improvements to the three KPIs Complexity, Ideality and Convergence
- **process performance vs phase equivalent industry averages** is quantified via RPG



use scorecard to effectively communicate the scientists' added value during process research & development




Green chemistry innovation scorecard



**Green
chemistry
innovation
scorecard**


Captures cEF and iGAL absolute numbers, reports out % ideality



Relative Process Greenness (RPG)
comparison to database, expressed as
% and category

**Green
chemistry
innovation
scorecard**


Captures cEF and iGAL absolute
numbers, reports out % ideality



Relative Process Greenness (RPG)
comparison to database, expressed as
% and category

**Green
chemistry
innovation
scorecard**

Captures cEF and iGAL
absolute numbers, reports out
% ideality




Process improvement
& innovation
demonstrated
by RPG upgrade

Relative Process Greenness (RPG)
comparison to database, expressed as
% and category

**Green
chemistry
innovation
scorecard**

Captures cEF and iGAL
absolute numbers, reports out
% ideality




Process improvement & innovation demonstrated by RPG upgrade

Amount waste saved expressed kg/kg and as %

Commercial Viagra process

2003 UK Institute of Chemical Engineers (IChemE)
Crystal Faraday Award for Green Chemical Technology




F. Roschangar, R. A. Sheldon and C. H. Senanayake *Green Chem.*, 2015, **17**, 752–768.

Guidance for **uniform** iGAL-cEF green chemistry analysis: F. Roschangar *et al.* *Green Chem.*, 2018, **20**, 2206–2211, ESI Discussion 2.

Exercise 1 - cEF


Q1: Determine cEF (= PMI – 1) for the following two-step sequence of the Viagra manufacturing process. How much waste do we generate for each kg of compound A? (*Note:* workup is included in analysis, but not reactor cleaning)



Step No.	Material	Input Weight	Output Weight
6	2-Ethoxybenzoic acid	0.43 kg	
	Thionyl Chloride	0.31 kg	
	Chlorosulfonic acid	1.26 kg	
	Water	7.47 kg	
	5-Chlorosulfonyl-2-ethoxy-benzoic acid (I1)		0.63 kg
7	5-Chlorosulfonyl-2-ethoxy-benzoic acid	0.63 kg	
	1-Methylpiperazine	0.55 kg	
	Water	4.77 kg	
	2-Ethoxy-5-(4-methyl-piperazine-1-sulfonyl)-benzoic acid (A)		0.67 kg

Exercise 1 - cEF

Q1: Determine cEF (= PMI – 1) for the following two-step sequence of the Viagra manufacturing process. How much waste do we generate for each kg of compound A? (*Note:* workup is included in analysis, but not reactor cleaning)



Step No.	Material	Input Weight	Output Weight
6	2-Ethoxybenzoic acid	0.43 kg	
	Thionyl Chloride	0.31 kg	
	Chlorosulfonic acid	1.26 kg	
	Water	7.47 kg	
	5-Chlorosulfonyl-2-ethoxy-benzoic acid (I1)		0.63 kg
7	5-Chlorosulfonyl-2-ethoxy-benzoic acid	0.63 kg	
	1-Methylpiperazine	0.55 kg	
	Water	4.77 kg	
	2-Ethoxy-5-(4-methyl-piperazine-1-sulfonyl)-benzoic acid (A)		0.67 kg


A1: m(all Inputs excl. intermediate I1) = 14.80 kg

$$cEF(A) = \frac{14.80 - 0.67}{0.67} = 21.1 \text{ kg of waste is generated per kg of A}$$

Exercise 2 – cEF and \$100 / mol rule

Q2: Determine cEF for the entire Viagra manufacturing process. How much waste do we generate for each kg of Viagra?


Step Number	Step cEF [kg waste / kg API]	Step Product needed to make 1 kg API [kg]	cEF Contribution to API Process Waste [kg waste / kg API]
1	12.1 kg/kg	0.72 kg	8.6 kg/kg
2	2.6 kg/kg	0.67 kg	1.8 kg/kg
3	16.9 kg/kg	0.57 kg	9.7 kg/kg
4	12.5 kg/kg	0.35 kg	4.4 kg/kg
5	25.2 kg/kg	0.42 kg	10.7 kg/kg
Subtotal for Step 5 Product (B)			35.1 kg/kg
6 + 7	21.1 kg/kg	0.67 kg	14.1 kg/kg
8	11.9 kg/kg	0.39 kg	4.6 kg/kg
9 + 10	13.9 kg/kg	0.81 kg	11.3 kg/kg
11	16.1 kg/kg	0.72 kg	11.6 kg/kg
12	8.7 kg/kg	1.00 kg	8.7 kg/kg
TOTAL			85.5 kg/kg



Exercise 2 – cEF and \$100 / mol rule

Q2: Determine cEF for the entire Viagra manufacturing process. How much waste do we generate for each kg of Viagra?

Step Number	Step cEF [kg waste / kg API]	Step Product needed to make 1 kg API [kg]	cEF Contribution to API Process Waste [kg waste / kg API]
1	12.1 kg/kg	0.72 kg	8.6 kg/kg
2	2.6 kg/kg	0.67 kg	1.8 kg/kg
3	16.9 kg/kg	0.57 kg	9.7 kg/kg
4	12.5 kg/kg	0.35 kg	4.4 kg/kg
5	25.2 kg/kg	0.42 kg	10.7 kg/kg
Subtotal for Step 5 Product (B)			35.1 kg/kg
6 + 7	21.1 kg/kg	0.67 kg	14.1 kg/kg
8	11.9 kg/kg	0.39 kg	4.6 kg/kg
9 + 10	13.9 kg/kg	0.81 kg	11.3 kg/kg
11	16.1 kg/kg	0.72 kg	11.6 kg/kg
12	8.7 kg/kg	1.00 kg	8.7 kg/kg
TOTAL			85.5 kg/kg



$$\mathbf{A2: } cEF(\text{Viagra}) = \sum_{\text{Step } 1}^{\text{Step } 12} cEF \text{ Contribution (Step } n) = 85.5 \text{ kg of waste per kg Viagra}$$

Exercise 2 – cEF and \$100 / mol rule

Q2: Determine cEF for the entire Viagra manufacturing process. How much waste do we generate for each kg of Viagra?

Q3: How much waste production would have been discounted if not using the \$100/mol starting material rule, and if the starting material was the Step 5 product?

Step Number	Step cEF [kg waste / kg API]	Step Product needed to make 1 kg API [kg]	cEF Contribution to API Process Waste [kg waste / kg API]
1	12.1 kg/kg	0.72 kg	8.6 kg/kg
2	2.6 kg/kg	0.67 kg	1.8 kg/kg
3	16.9 kg/kg	0.57 kg	9.7 kg/kg
4	12.5 kg/kg	0.35 kg	4.4 kg/kg
5	25.2 kg/kg	0.42 kg	10.7 kg/kg
Subtotal for Step 5 Product (B)			35.1 kg/kg
6 + 7	21.1 kg/kg	0.67 kg	14.1 kg/kg
8	11.9 kg/kg	0.39 kg	4.6 kg/kg
9 + 10	13.9 kg/kg	0.81 kg	11.3 kg/kg
11	16.1 kg/kg	0.72 kg	11.6 kg/kg
12	8.7 kg/kg	1.00 kg	8.7 kg/kg
TOTAL			85.5 kg/kg




$$\mathbf{A2: } cEF(\text{Viagra}) = \sum_{\text{Step } 1}^{\text{Step } 12} cEF \text{ Contribution (Step } n) = 85.5 \text{ kg of waste per kg Viagra}$$

Exercise 2 – cEF and \$100 / mol rule

Q2: Determine cEF for the entire Viagra manufacturing process. How much waste do we generate for each kg of Viagra?

Q3: How much waste production would have been discounted if not using the \$100/mol starting material rule, and if the starting material was the Step 5 product?

Step Number	Step cEF [kg waste / kg API]	Step Product needed to make 1 kg API [kg]	cEF Contribution to API Process Waste [kg waste / kg API]
1	12.1 kg/kg	0.72 kg	8.6 kg/kg
2	2.6 kg/kg	0.67 kg	1.8 kg/kg
3	16.9 kg/kg	0.57 kg	9.7 kg/kg
4	12.5 kg/kg	0.35 kg	4.4 kg/kg
5	25.2 kg/kg	0.42 kg	10.7 kg/kg
Subtotal for Step 5 Product (B)			35.1 kg/kg
6 + 7	21.1 kg/kg	0.67 kg	14.1 kg/kg
8	11.9 kg/kg	0.39 kg	4.6 kg/kg
9 + 10	13.9 kg/kg	0.81 kg	11.3 kg/kg
11	16.1 kg/kg	0.72 kg	11.6 kg/kg
12	8.7 kg/kg	1.00 kg	8.7 kg/kg
TOTAL			85.5 kg/kg



A2: $cEF(Viagra) = \sum_{Step\ 1}^{Step\ 12} cEF\ Contribution\ (Step\ n) = 85.5\ kg\ of\ waste\ per\ kg\ Viagra$

A3: We would have neglected $cEF(B) = [\sum_{Step\ 1}^{Step\ 5} cEF\ Contribution\ (Step\ n)] = 35.1\ kg\ of\ waste\ per\ kg\ Viagra$, or **41%** of overall waste! → **importance of standardization**

Exercise 3 – iGAL and RPG

Q4: Determine the commercial green manufacturing waste target for the Viagra process based on the drug's complexity as reflected *via* its FMW. What is its Green Aspiration Level (GAL)? (Note: FMW(Viagra) = 474.6 g/mol)

Table 3 iGAL-based RPG Rating Matrix for green drug manufacturing

Percentile (PCTL)	Code	Rating	Minimum RPG for		
			Early Dev	Late Dev	Commercial
90%		Excellent	66%	146%	222%
70%		Good	48%	103%	168%
40%		Average	29%	59%	113%
		Below Average			

Exercise 3 – iGAL and RPG

Q4: Determine the commercial green manufacturing waste target for the Viagra process based on the drug's complexity as reflected *via* its FMW. What is its Green Aspiration Level (GAL)? (Note: FMW(Viagra) = 474.6 g/mol)

Table 3 iGAL-based RPG Rating Matrix for green drug manufacturing

Percentile (PCTL)	Code	Rating	Minimum RPG for		
			Early Dev	Late Dev	Commercial
90%		Excellent	66%	146%	222%
70%		Good	48%	103%	168%
40%		Average	29%	59%	113%
		Below Average			

A4: $iGAL = 0.344 \times FMW = 163.3 \text{ kg}$ waste target per kg Viagra. This reflects the complexity-adjusted waste produced by the *average* commercial drug mfg. process.

Exercise 3 – iGAL and RPG

Q4: Determine the commercial green manufacturing waste target for the Viagra process based on the drug's complexity as reflected *via* its FMW. What is its Green Aspiration Level (GAL)? (Note: FMW(Viagra) = 474.6 g/mol)

Q5: How does the process compare to others? Determine Relative Process Greenness (RPG). How much greener is this process vs. 'same-phase' industry averages? (Note: commercial RPG avg. = 131%)

Table 3 iGAL-based RPG Rating Matrix for green drug manufacturing

Percentile (PCTL)	Code	Rating	Minimum RPG for		
			Early Dev	Late Dev	Commercial
90%		Excellent	66%	146%	222%
70%		Good	48%	103%	168%
40%		Average	29%	59%	113%
		Below Average			

A4: $iGAL = 0.344 \times FMW = 163.3 \text{ kg}$ waste target per kg Viagra. This reflects the complexity-adjusted waste produced by the *average* commercial drug mfg. process.

Exercise 3 – iGAL and RPG

Q4: Determine the commercial green manufacturing waste target for the Viagra process based on the drug's complexity as reflected *via* its FMW. What is its Green Aspiration Level (GAL)? (Note: FMW(Viagra) = 474.6 g/mol)

Q5: How does the process compare to others? Determine Relative Process Greenness (RPG). How much greener is this process vs. 'same-phase' industry averages? (Note: commercial RPG avg. = 131%)

Table 3 iGAL-based RPG Rating Matrix for green drug manufacturing

Percentile (PCTL)	Code	Rating	Minimum RPG for		
			Early Dev	Late Dev	Commercial
90%		Excellent	66%	146%	222%
70%		Good	48%	103%	168%
40%		Average	29%	59%	113%
		Below Average			

A4: $iGAL = 0.344 \times FMW = 163.3 \text{ kg}$ waste target per kg Viagra. This reflects the complexity-adjusted waste produced by the *average* commercial drug mfg. process.

A5: $RPG = \frac{iGAL}{cEF} \times 100\% = \frac{163.3}{85.5} \times 100\% = 191\%$.

The Viagra process produces $191\%/131\% = 1.45$ times less waste than the commercial average industry process.

Exercise 3 – iGAL and RPG

Q4: Determine the commercial green manufacturing waste target for the Viagra process based on the drug's complexity as reflected *via* its FMW. What is its Green Aspiration Level (GAL)? (Note: FMW(Viagra) = 474.6 g/mol)

Q5: How does the process compare to others? Determine Relative Process Greenness (RPG). How much greener is this process vs. 'same-phase' industry averages? (Note: commercial RPG avg. = 131%)

Q6: Use RPG rating matrix¹ to rate the commercial Viagra process.

Table 3 iGAL-based RPG Rating Matrix for green drug manufacturing

Percentile (PCTL)	Code	Rating	Minimum RPG for		
			Early Dev	Late Dev	Commercial
90%		Excellent	66%	146%	222%
70%		Good	48%	103%	168%
40%		Average	29%	59%	113%
		Below Average			

A4: $iGAL = 0.344 \times FMW = 163.3 \text{ kg}$ waste target per kg Viagra. This reflects the complexity-adjusted waste produced by the *average* commercial drug mfg. process.

A5: $RPG = \frac{iGAL}{cEF} \times 100\% = \frac{163.3}{85.5} \times 100\% = 191\%$.

The Viagra process produces $191\%/131\% = 1.45$ times less waste than the commercial average industry process.

Exercise 3 – iGAL and RPG

Q4: Determine the commercial green manufacturing waste target for the Viagra process based on the drug's complexity as reflected *via* its FMW. What is its Green Aspiration Level (GAL)? (Note: FMW(Viagra) = 474.6 g/mol)

Q5: How does the process compare to others? Determine Relative Process Greenness (RPG). How much greener is this process vs. 'same-phase' industry averages? (Note: commercial RPG avg. = 131%)

Q6: Use RPG rating matrix¹ to rate the commercial Viagra process.

Table 3 *iGAL*-based RPG Rating Matrix for green drug manufacturing

Percentile (PCTL)	Code	Rating	Minimum RPG for		
			Early Dev	Late Dev	Commercial
90%		Excellent	66%	146%	222%
70%		Good	48%	103%	168%
40%		Average	29%	59%	113%
		Below Average			

A4: $iGAL = 0.344 \times FMW = 163.3 \text{ kg}$ waste target per kg Viagra. This reflects the complexity-adjusted waste produced by the *average* commercial drug mfg. process.

A5: $RPG = \frac{iGAL}{cEF} \times 100\% = \frac{163.3}{85.5} \times 100\% = 191\%$.


The Viagra process produces $191\%/131\% = 1.45$ times less waste than the commercial average industry process.

A6: With RPG = 191% the commercial Viagra process falls into the top 30% and is rated **GOOD**.

How to inspire green process innovation via iGAL?



Use **iGAL** to capture value and innovation impact



Communicate value



Motivate innovation via a new **Green Chemistry Innovation Scorecard**

RPG rating matrix for process evaluation:

based on average commercial waste

Example: Dabigatran (3rd gen process)

RPG = 243%

Percentile (PCTL)	Code	Rating	Minimum RPG for		
			Early dev.	Late dev.	Commercial
90%	Green	Excellent	66%	146%	222%
70%	Light Green	Good	48%	103%	168%
40%	Yellow	Average	29%	59%	113%
	Orange	Below average			

Example: Viagra process

RPG = 191%

iGAL summary



$$\begin{aligned}RPG &= \frac{iGAL}{cEF} \times 100\% \\ &= \frac{0.344 \times FMW}{cEF} \times 100\%\end{aligned}$$



Standardized: apply \$100/mol rule for starting materials (lab catalog pricing)



Consistent: include all process and workup materials, but exclude reactor cleaning



Fair: compare your process to industry averages from same development phase.
Consider molecular complexity via FMW



Simple: determine FMW and process waste ($cEF = PMI - 1$) for an API campaign



Quantitative: assess your process vs. industry & determine your process improvements

use web-based [Green Chemistry Innovation Scorecard Calculator](#)

Outlook



Green Chemistry



Throughout Development

Leverage iGAL goal in conjunction with Green Chemistry Innovation Scorecard to motivate internal and external waste & cost reduction

Early Development

Establish the “ideal synthesis route” to enable maximum future process greenness with respect to co-produced waste

Late Development

Optimize the “ideal synthesis route” with respect to Life Cycle Assessment

Overall Summary

Chemists and engineers have enormous control over manufacturing processes by selection of synthetic routes

The 12 green chemistry principles are terrific guiding rules

Solvent and reagent selection guides, coupled with metrics and life cycle analysis can help make routes more sustainable

Metrics are vital – *you can't manage what you don't measure*

Green chemistry triple win: cost-effective, better for environment, safer for stakeholders (employees, community)

iGAL team

Amgen
 Bayer
 Boehringer Ingelheim
 Bristol-Myers Squibb
 Genentech / Roche
 GSK
 Lilly
 Merck
 Novartis
 Pfizer
 Takeda
 Teva

12 pharmaceutical firms



3 universities



2 industry consortia



- This presentation was developed with the support of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ, www.iqconsortium.org). IQ is a not-for-profit organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader research and development community.